Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs.

Candidemia has been considered a persistent public health problem with great impact on hospital costs and high mortality. We aimed to evaluate the epidemiology and prognostic factors of candidemia in a tertiary hospital in Northeast Brazil from January 2011 to December 2016. Demographic and clinical data of patients were retrospectively obtained from medical records and antifungal susceptibility profiling was performed using the broth microdilution method. A total of 68 episodes of candidemia were evaluated. We found an average incidence of 2.23 episodes /1000 admissions and a 30-day mortality rate of 55.9%. The most prevalent species were Candida albicans (35.3%), Candida tropicalis (27.4%), Candida parapsilosis (21.6%) and Candida glabrata (11.8%). Higher mortality rates were observed in cases of candidemia due to C . albicans (61.1%) and C . glabrata (100%), especially when compared to C . parapsilosis (27.3%). Univariate analysis revealed some variables which significantly increased the probability of death: older age ( P = 0.022; odds ratio [OR] = 1.041), severe sepsis ( P < 0.001; OR = 8.571), septic shock ( P = 0.035; OR = 3.792), hypotension ( P = 0.003; OR = 9.120), neutrophilia ( P = 0.046; OR = 3.080), thrombocytopenia ( P = 0.002; OR = 6.800), mechanical ventilation ( P = 0.009; OR = 8.167) and greater number of surgeries ( P = 0.037; OR = 1.920). Multivariate analysis showed that older age ( P = 0.040; OR = 1.055), severe sepsis ( P = 0.009; OR = 9.872) and hypotension ( P = 0.031; OR = 21.042) were independently associated with worse prognosis. There was no resistance to amphotericin B, micafungin or itraconazole and a low rate of resistance to fluconazole (5.1%). However, 20.5% of the Candida isolates were susceptible dose-dependent (SDD) to fluconazole and 7.7% to itraconazole. In conclusion, our results could assist in the adoption of strategies to stratify patients at higher risk for developing candidemia and worse prognosis, in addition to improve antifungal management.

No abstract

No abstract